At what enterprise value was BANOOK acquired in 2023?

You can find the full valuation details of BANOOK on mynth capital. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 15.6x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of BANOOK when it was acquired by MOTION EQUITY PARTNERS?

The exact EV/EBITDA multiple for BANOOK is available on mynth capital. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 15.6x. Join our community for free to access full valuation data and industry trends.

When was BANOOK acquired by MOTION EQUITY PARTNERS?

BANOOK was acquired by MOTION EQUITY PARTNERS in 2023.

What was the revenue of BANOOK at the time of the deal?

The revenue of BANOOK at the time of the deal is estimated to be in the range of 5M - 25M EUR. Register for free to access the full transaction report and exact valuation multiples.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the BANOOK acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the BANOOK deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://capitalfinance.lesechos.fr/deals/lbo/motion-equity-partners-relaie-turenne-chez-banook-1989085

← DATABASE

Home Database Healthcare & PharmaBANOOK

10/2023

BANOOK acquired by MOTION EQUITY PARTNERS

FRANCE Healthcare Services / CRO / Clinical Trials REV 5M - 25M EUR

Context

Motion Equity Partners acquired a majority stake in Banook Group from Turenne Sante. The transaction was structured as a growth-oriented LBO, with the management team and Turenne Sante reinvesting substantially. The primary goal was to provide Banook with the resources to accelerate its buy-and-build strategy, focusing on North American expansion and diversification into eCOA and biostatistics.

BANOOK, which reported an EBITDA margin of in 2022, is valued in this transaction at an EV/EBITDA multiple of , a level to compare with the average currently observed in the Healthcare & Pharma sector (15.6x).

-> Deep-dive in Healthcare & Pharma market trends

Target

Founded in 1999 in Nancy, Banook has established itself as a Cardiac Safety Central Service Provider specialized in the centralization of cardiac data derived from electrocardiograms (ECG) and central imaging within the context of clinical trials. For over 25 years, Banook has been a trusted partner for pharmaceutical laboratories, biotechnology companies, and generalist Contract Research Organizations (CROs), streamlining drug candidates safety and efficacity assessment by centralizing and analyzing ECG and medical imaging data.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2022

2021

Similar deals in Healthcare Services

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
06/2024	PERMIRA	PHARMACORD	UNITED STATES	Health Tech
05/2024	21 INVEST / OAKLEY CAPITAL INVESTMENTS	PRODUCT LIFE	FRANCE	Healthcare Services
09/2023	CERBA HEALTHCARE	CIRION BIOPHARMA RESEARCH	CANADA	CRO / Clinical Trials
09/2023	PERMIRA	ERGOMED	UNITED KINGDOM	CRO / Clinical Trials
06/2023	SUPERNOVA INVEST / HEAL CAPITAL	GLEAMER	FRANCE	Health Tech
06/2022	ASTORG	OPEN HEALTH	UNITED STATES	Healthcare Services
11/2020	KERSIA	SOPURA	BELGIUM	Sterilization & Hygiene
10/2020	IK PARTNERS	KERSIA	FRANCE	Sterilization & Hygiene
05/2020	CLAYTON, DUBILIER & RICE (CD&R)	HUNTSWORTH	UNITED KINGDOM	Healthcare Services
01/2018	SPECTRIS	CONCEPT LIFE SCIENCES	UNITED KINGDOM	CRO / Clinical Trials

REFERENCES

Revenue range: 5M - 25M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of BANOOK by MOTION EQUITY PARTNERS are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Acquirer: motion equity partners